Terminated × Myelodysplastic Syndromes × Breast × Clear all
NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
NCT00651716 2019-11-15

T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Vanderbilt-Ingram Cancer Center

Terminated
150 enrolled
NCT02431260 2019-06-14

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
69 enrolled 34 charts
NCT02900248 2019-04-02

N1

CureOne

Terminated
23 enrolled
NCT00617929 2017-12-28

Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant

Masonic Cancer Center, University of Minnesota

Phase 2 Terminated
12 enrolled 12 charts
NCT00324324 2017-05-09

Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant

OHSU Knight Cancer Institute

Phase 3 Terminated
240 enrolled
NCT00900068 2017-05-09

Blood Samples From Patients on a Clinical Trial to CINV During HSCT

OHSU Knight Cancer Institute

Terminated
9 enrolled
NCT00946283 2017-02-03

Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome

Rutgers, The State University of New Jersey

Phase NA Terminated
30 enrolled